SILO PHARMA, INC. Available-for-sale Equity Securities, Gross Unrealized Loss
SILO PHARMA, INC. (SILO) reported Available-for-sale Equity Securities, Gross Unrealized Loss of $457.80 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-05-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss · last filed 2021-05-17
- SILO PHARMA, INC. available-for-sale equity securities, gross unrealized loss for fiscal 2020 was $457.80K, a 343.90% increase from fiscal 2019.
- SILO PHARMA, INC. available-for-sale equity securities, gross unrealized loss for fiscal 2019 was $103.13K, a 34.57% increase from fiscal 2018.
- SILO PHARMA, INC. available-for-sale equity securities, gross unrealized loss for fiscal 2018 was $76.64K.
| Period end | Available-for-sale Equity Securities, Gross Unrealized Loss 12 month |
|---|---|
| 2020-12-31 | $457.80K 10-K/A · filed 2021-05-17 |
| 2019-12-31 | $103.13K 10-K/A · filed 2021-05-17 |
| 2018-12-31 | $76.64K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |